The distribution of the age-adjusted international prognostic index was 12/95 (13%) high risk, 20/95 (21%) high-intermediate risk and 63/95 (66%) low/low-intermediate risk. Bulky disease was found in 24% of the cases, anemia in 33 of 76 patients and bleeding in 22 of 72 patients. The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) estimates 4-year progression-free survival and 4-year overall survival for patients with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL). Symptoms included abdominal pain (63/74), weight loss (57/73), dysphagia (37/72) and nausea/vomiting (37/72). Does not identify any risk group with 4-year survival <50%; … This international prognostic index (IPI) score calculator for lymphoma prognosis stratifies survival rates based on risk factors in the original and revised IPI scores. Of 104 patients, 57 were female and the median age was 69 years (range: 28–88). A simplified index can be used when comparing patients within an age group (i.e. Important clinical prognostic factors that are correlated with an adverse outcome include poor performance status, splenomegaly, anemia, and age. At a median follow-up of 4 years, the PFS and OS are 28% and 34% by intention to treat and 39% and 45% for only those patients with chemosensitive disease. 60 or younger, or over 60) and includes only 3 of the above factors: We evaluated the age-adjusted International Prognostic Index at the initiation of second-line therapy (sAAIPI) as a predictor of progression-free survival (PFS) and overall survival (OS). The distribution of the age-adjusted international prognostic index was 12/95 (13%) high risk, 20/95 (21%) high-intermediate risk and 63/95 (66%) low/low-intermediate risk. Recently, NCCN-IPI 2 was stated to be a better predictor of prognosis for DLBCL in rituximab era. There is in depth information about the two versions of this lymphoma prognostic index and also … Introduction. In pre-rituximab era, the IPI has been developed and widely used to predict the prognosis of aggressive lymphoma while Miller's stage modified IPI 1 was reported as a better prognostic model for limited stage DLBCL. 24, 29, 30 Contradictory reports on the value of the International Prognostic Index (IPI), 31 which considers age (≤60 years vs. >60 years), performance status (ECOG 0-1 vs. 2-4), Ann Arbor stage (I-II vs. III-IV), extranodal involvement (less than two vs. two … international prognostic index for aggressive non-hodgkin's lymphoma n engl j med 1993;329:987. age-adjusted ipi (for patients 60 years old or less) The R-IPI provides greater discrimination amongst DLBCL patients with differing survival based on easily obtained factors.